EGA Calls for Removal of Barriers to Generics in Europe
Adrian van den Hoven, Director General of the European Generics Association (EGA), this week called for the removal of barriers to generic medicines across the European Union.
Adrian van den Hoven, Director General of the European Generics Association (EGA), this week called for the removal of barriers to generic medicines across the European Union.
Speaking at the 5th Bruges European Business Conference, van den Hoven maintained that the move would be in the interest of creating a pro-competitive pharmaceutical market in the EU and fostering sustainable competition.
He underlined the crucial role for Europe as a strong EU pharmaceutical export base, to be achieved through regulatory convergence with key trade partners and regulatory approximation in the EU with developing and emerging countries.
The Bruges conference was hosted by the College of Europe and included representatives from the European institutions, national governments and academia, and business leaders from all industrial sectors. Speakers included Dr. Wolfgang Schauble, German Minister of Finance and Prof. Mario Monti, former European Commissioner and Italian Prime Minister.
This entry was posted in
Europe
,
Events
,
Global
,
Regulatory
and tagged
Bruges European Business Conference
,
EGA
,
EU
,
European Generics Association
,
generics
. Bookmark the
permalink
. Trackbacks are closed, but you can
post a comment
.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
